Trial
NCT06430905
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hookipa Biotech GmbH
Collaborators
—
Condition
Human Immunodeficiency Virus (HIV) Infection
Intervention
HB-502 and HB-501 alternating 2-vector therapy Dose Level 1
Why stopped
business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-18